IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

Phase 0 Not yet recruiting 12 enrolled Beijing Immunochina Medical Science & Technology Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy

Timeline

Start: 2024-12-13
Primary completion: 2025-08-04
Completion: 2026-12-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IM19	Cell therapy	5e+07 cells	—
Subject	IM19	Cell therapy	1e+08 cells	—

IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

Summary

Timeline

Drugs

Indications